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Abstract
This is an overview of the current trends in the management of high-grade gliomas
based on the current evidence available at the time of compiling this chapter in the first
quarter of 2016, by a dedicated, high-volume Neurosurgical Oncology team of clinical
and surgical Neuro-Oncologists based in central Pennsylvania.
Keywords: High-grade glioma, glioblastoma, malignant brain tumor, brain tumor, in‐
trinsic glioma
1. Introduction
The year 2016 continues to be both an enlightening and an exciting year for advances in the
investigation and management of high-grade gliomas. The hallmark of glioblastomas is their
molecular and genetic heterogeneity, the ability to infiltrate diffusely and undergo rapid
neoangiogenesis, while actively challenging our current combinatorial therapeutic approach.
At the time of writing, over 230 clinical trials were open in the USA, with ongoing recruitment
or due to start. This overview of current trends will involve the details of the molecular markers
now in use for both the diagnosis and prognostication of high-grade gliomas, updates on
neuroimaging guidelines for both de novo and secondary high-grade gliomas, and the discussion
of potential adjuvant therapies to the current standard of care.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Twenty-first century epidemiological trends
The most recent 2015 Statistical Report of the Central Brain Tumor Registry [1] documents the
epidemiology of glioblastomas from 2008 to 2012. Glioblastomas remain the most common
malignant histology (46.1%) of all primary malignant brain tumors, with an age-proportion‐
al incidence peaking at the ninth decade of life (age range 75-84 years). Of interest, glioblas‐
tomas have been shown to be 1.6 times more common in males, twice as common in
Caucasians, and only 5.1% of patients survive five years after diagnosis.
3. The genetic risk of glioma
The lifetime risk of gliomas is 4-5 per 1000 of the general population. Thus, inheriting of one
of the low penetrance glioma risk variants may increase the risk by 20-40% to approximately
6 per 1000 [2]. The risk loci of glioma variants have been identified as ten inherited variants
near eight genes, 2 with stratification leading to an increase in the risk of developing gliomas.
The common inherited variants are named for the nearby genes of TERC, TERT, EGFR,
CDKN2B, PHLDB1, CCDC26, TP53 and RTEL1, and are not directly involved in protein
coding [3]. Of interest, these variants increase the odds ratio of gliomagenesis on a scale of 1.2–
1.4. TERT, TERC, and RTEL1 are involved in telomere maintenance, and it has been hypothe‐
sized that a longer telomere length may possibly contribute to risk of gliomas [4, 5].
Additionally, of note, is the predictive and prognostic value of gliomas with TERT gene
promoter mutations in association with isocitrate dehydrogenase (IDH) mutations and loss of
heterozygosity of 1p/19q [4]. The less common risk loci are noted to correlate with higher odds
ratios, and these are located near TP53 (2.4-fold increase in relative risk) and CCDC26 (6.3-fold
increase in relative risk) especially in the presence of an IDH mutation or an oligodendro‐
glial component. Moreover, the UCSF Adult Glioma Study noted that population screening
for the risk loci near the CCDC26 yielded significantly more false positives than true posi‐
tives, and hence the yield for undertaking this screening test of risk loci was extremely low [2].
At this point, with our current knowledge arsenal, the authors advise the following three
acquired molecular glioblastoma markers to be identified and then further correlate to survival
and outcome: IDH mutation, 1p/19q, and TERT promoter mutation. These molecular glio‐
blastoma markers are then further subdivided into five glioma subgroups to further elicit the
pathways of gliomas in pathways: TERT mutated only (most common in approximately half
of the cases), IDH mutated only, TERT and IDH mutation (least common), triple negative and
triple positive [6, 7]. Of note, the IDH mutation status was analyzed in the BELOB trial, which
showed a lower median overall survival for patients with wild-type IDH (8 months) com‐
pared with median survival of 20 months for patients with an IDH mutational status [8]. We
also note here, in our clinical role as Neurosurgical Oncologists, of the recent landmark paper
associating a definite survival benefit after maximal surgical resection, including both
enhancing and nonenhancing tumor, resulting in an improved prognosis observed in the IDH1
mutant subgroup [9]. Thus, individualized surgical strategies for high-grade gliomas must be
considered on the molecular IDH marker status of the tumor [10].
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The recent development of a targeted next-generation sequencing panel (GlioSeq) provides
simultaneous, highly accurate and comprehensive genetic profiling of a wide array of central
nervous system (CNS) tumors on an increasingly smaller volumes of biopsies in a single
workflow format [11]. This next-generation assay allows simultaneous detection of the major
mutations (>1360 hot spots in 30 CNS tumor-related genes) in addition to 14 gene fusions and 24
gene copy number changes in a rapid and cost-effective manner. We look forward to the
incorporation of the versatile GlioSeq as a high throughput technological advance to rapidly
identify a variety of genetic alterations and small deletions, thereby assisting in diagnosis and
prognostic stratification of brain tumors.
Finally, the Neuro-Oncology community looks forward to the Glioma International Case-
Control Consortium undertaking the important task of identification of new risk loci by the
genotyping of 4000 glioma and 4000 nonglioma patients in the Epi4K project (epgb.org/epi4k).
4. Neuro-radiological updates for high-grade gliomas
The updated aims of the working group of the Response Assessment in Neuro-Oncology
(RANO) continue to provide guidelines for a uniform criteria for the assessment of determin‐
ing the progression and treatment response of high-grade gliomas [12]. RANO guidelines will
be discussed in detail here, as it is imperative to emphasize the clinical need for consistency
and standardization of imaging, for a reliable assessment of tumor burden and progression.
The RANO guidelines refer to the reliability of imaging data and reproducibility of the
acquired results to be undertaken no later than 72 hours postsurgical resection and is deter‐
mined by the standardization of gadolinium dose, slice thickness ≥5 mm or no more than twice
the thickness of a measurable lesion. We now describe RANO guidelines nomenclature as per
the updated guidelines [12, 13]:
• Measurable lesions are bidimensionally contrast-enhancing, with clearly defined mar‐
gins in two perpendicular diameters, each measuring at least 10 mm in diameter.
• Nonmeasurable lesions refer to those with maximal diameters of <10 mm, masses with
poorly defined margins (cysts, necrotic lesions, and leptomeningeal tumors) and nonen‐
hancing lesions only seen on FLAIR/T2. Hence, for nonmeasurable lesions, continued
radiological surveillance may indicate only the attainment of clinical plateau of stable
disease, versus the response rate of measurable lesions as a response or failure to therapy
in radiological follow-up.
Furthermore, there are four RANO categories to treatment response:
• Complete response
This refers to the lack of all enhancing lesions for a minimum of four weeks and the
appearance of new lesions, this should be married to the patients’ clinical picture of stability
or response, whilst weaning or off steroids.
• Partial response
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This refers to no progression of nonmeasurable lesions and no new lesions. Specifically, this
is defined as ≥50% decrease in sum of all products of diameters (SPD) of all target lesions
with stable clinical symptomatology and a stable steroid dose.
• Progressive disease
This differs from partial response with having ≥25% increase in the sum of target lesions,
with significant increase in nonenhancing lesions, with clinical deterioration with no
decrease in steroid dose and/or a new radiological lesion.
• Stable disease
This is the radiological diagnosis of exclusion of neither complete nor partial response, with
lack of progression seen.
As per the RANO guidelines, criteria for progressive disease is met when the majority of new
enhancement is noted beyond the 80% isodose line of radiotherapy or on histopathological confirmation.
This is an important point for us to bear in mind, as a third of glioblastoma patients may be reported on
as undergoing pseudoprogression, thus this term needs to be utilized in accordance with the RANO
guidelines. Also of importance, is the pseudoresponse seen post-antiangiogenic therapy (anti-vascular
endothelial growth) which decrease the permeability of the blood-brain barrier thereby decreasing the
gadolinium enhancement [14]. Radiological surveillance with T2/FLAIR is sensitive in identifying
vasogenic edema and used in combination with DWI is a increases the likelihood of identifying tumor
burden [15]. An improvement in T2/FLAIR is associated with improved survival and decreased
mortality, DWI remains an independent predictor of progression free survival at 6 months [12, 15].
RANO guidelines state that all radiological responses must persist for four weeks prior to be
considered ‘true’ progression or response: this is the crux of the RANO guidelines.
5. Immunotherapy
Glioblastomas undertake a host of immunosuppressive mechanisms, resulting in challenges
for the immunotherapeutic interventions [16]. In this subsection, we discuss the immunother‐
apy and the use and rationale of trials and their application.
Optimal antitumor therapy needs to have an antigen as an immunological target along with
the activation of the immune system for facilitating trafficking and infiltration of the now
activated immune system targeting the tumor.
Let us start by overviewing the multiple key immunosuppressive mechanisms existing within
the highly plastic glioblastoma microenvironment. Regulatory T cells (Tregs) are produced
within the thymus (nTregs) or are induced (iTregs). Of the two, nTregs are noted in higher
concentration within the glioblastoma tumor clusters [16]. Immunosuppressive mechanisms
have been directly correlated to, by identifying the cytokines within the tumor cysts fluid
secreted by the Tregs: transforming growth factor beta [TGF-β] and interleukin 10 [IL-10].
Inhibitors of TGF-β receptor kinase are currently in preclinical testing. Up to a tenth of the
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mass of glioblastomas consist of the tumor-associated macrophages (M2 linage) and micro‐
glia. The aggressiveness of glioma-stem cells is enhanced by the secretion of TGF-β by the
tumor-associated macrophages. The glioblastoma stem cells increase the number of circulat‐
ing Tregs and also activate the signal transducer and activator of transcription 3 (STAT 3),
which is found to be ubiquitously expressed in glioblastoma cells [16].
High-grade glioma progression has also been shown to be enhanced in the presence of glioma-
secreted colony stimulating factor 1 (CSF-1) to cause polarization of tumors toward the glioma-
supportive (M2) phenotype [17]. Of note, the vascular endothelial growth factor (VEGF) has
multiple functions of tumorigenesis and simultaneously of inhibition of dendritic cell function.
We discuss the role of anti-VEGR receptor agents in further detail below in subsection 6.
Immune checkpoint programmed death PD-1 binds the ligand for PD-1 (PD-L1) to suppress
CD4+ and CD8+ cells. PD-L1 is upregulated in gliomas, specifically the mesenchymal subtype
of glioblastomas and has been associated with inhibition and apoptosis of T cells. Anti-PD1
blockade has been undertaken in the murine glioblastoma models successfully with an
increase in survival, in combination with radiotherapy [18].
Cytotoxic T-Lymphocyte-associated protein 4 (CTLA-4) is an inhibitory surface receptor found
on constitutionally active Tregs, and hence, is the other immune checkpoint inhibitor of great
clinical interest [19, 20]. The FDA has recently approved ipilimumab, a monoclonal antibody
directed against CTLA-4, after Phase III trials for melanoma patients showed an objective
increase in survival. In the murine model, anti-CTLA-4 and IL-12 administration demonstrat‐
ed a reduction in Tregs and increased immune effector response, which is now under
investigation for glioblastoma therapies [21, 22].
An investigational immunotherapeutic agent that has been in the limelight for the past couple
of years is RINTEGA® (Rindopepmut CDX-110). RINTEGA® is administered intradermally
and consists of the EGFRvIII-specific peptide sequence conjugated to keyhole limpet hemo‐
cyanin, thereby stimulating pronounced EGFRvIII-specific humoral and cellular responses
resulting in the production of anti-EGFRvIII antibodies infiltrating and attacking the tumor.
EGFRvIII is a tumor-specific oncogene and a mutated form of the epidermal growth factor
receptor (EGFR), which is noted in one-third of all GBM cases with aggressive tumor prolif‐
eration and correspondingly poor median survival compared with other glioblastoma cases
[23–25]. EGFRvIII is not expressed in normal tissue, hence making it a unique immunothera‐
peutic target.
Hence, at this point, we will dedicate a few lines to the discontinuation of the ACT IV study
in March 2016 based on the recommendation of the Data Safety and Monitoring Board and an
update has appeared on the Celldex Therapeutics website. ACT IV was a Phase III study
conducted in newly diagnosed EGFRvIII-positive glioblastoma patients with RINTEGA® and
granulocyte-macrophage colony stimulating factor added to standard of care temozolamide
with the control arm regimen undergoing standard of care temozolamide plus intradermal
keyhole limpet hemocyanin. The control arm significantly outperformed expectations
(hazard ratio = 0.99; median OS: RINTEGA 20.4 months vs. control 21.1 months) and hence
the study showed an inability to meet the primary outcome survival endpoint.
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The ReACT study is the randomized, Phase II trial of RINTEGA® in combination with
bevacizumab (Avastin®) in patients with recurrent EGFRvIII-positive glioblastoma. In
November 2015, Celldex Therapeutics reported long-term survival data in group 1 (bevaci‐
zumab-naive patients randomized to receive either RINTEGA or a control injection of KLH in
a blinded fashion; all patients also received bevacizumab) at the Society for Neuro-Oncology
Annual Meeting. At two years, the survival rate was 25% for patients in the RINTEGA arm
versus 0% for patients in the control arm, with continuing advantage shown across multiple
endpoints [26].
6. Anti-angiogenic treatments
The pathological angiogenesis of glioblastomas is a hallmark of the disease process, with
multiple mechanisms hypothesized, including the transdifferentiation of tumor cells into
endothelial cells, vascular mimicry, and vessel co-opting [27]. Tumor angiogenesis has been
shown to be associated with the recruitment of hematopoietic and circulating precursor cells
[28].
The VEGF (vascular endothelial growth factor) pathway is highly expressed in glioma
angiogenesis with overexpression of VEGF-A. There have been a multitude of factors
identified to propagate and inhibit the VEGF pathway, including hypoxia inducible angio‐
genic factors, and endogenous factors like placenta growth factor. The anti-VEGF/VEGR
compounds inhibit the proliferation of endothelial cells and neoangeogenesis, with a corre‐
sponding decrease in the permeability of the blood–brain barrier. Within 48 hours of anti-
VEGF-A therapy with bevacizumab (Avastin®), there is decreased contrast enhancement,
which may be misleading and hence to be read as a pseudoresponse. In contrast the T2/FLAIR
progression is seen on serial radiological imaging, which has been postulated to be a nonan‐
giogenic invasive growth pattern and the likelihood of T2 progress predicting subsequent T1
and in turn tumor progression [14, 29]. Hence, our above discussion on RANO criteria will be
called upon here to be borne in mind while analysing the imaging characteristics of patients
on antiangiogenic therapy.
Bevacizumab (Avastin®) is the antibody to VEGF-A which has been utilized in Phase I, II and
III trials to investigate its role in both newly diagnosed and recurrent glioblastoma. Of note,
the AVAglio (Avastin® in Glioblastoma) study was undertaken in a for newly diagnosed
glioblastoma patients in a randomized manner (bevacizumab versus placebo) with double-
blinding. Postsurgical resection, the patients were commenced on the Stupp protocol
(concurrent radiotherapy 2 Gy 5 days a week and temozolomide 75 mg/kg) in combination
with intravenous bevacizumab 10 mg/kg (or placebo) every fortnight. After a 28-day treat‐
ment break, the patients were commenced on a maintenance dose of temozolomide (150–
200 mg/kg) and fortnightly intravenous bevacizumab (10 mg/kg) or placebo for 6 weeks. This
was followed by bevacizumab (10 mg/kg) every three weeks as monotherapy. The patients
were assessed clinically at predetermined, regular time points. The results of the AVAglio
study echoed those of the Phase III Radiation Therapy Oncology Group (RTOG-0825) with
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both studies showing a trend toward increase in progression free survival but no significant
difference in overall survival [30, 31]. It is important to note, as with other previous studies,
the adverse effects of the bevacizumab group were noted to be higher than in the placebo group
and noted to include hypertension, proteinuria, and (arterial) thromboembolism. The question
arises regarding the failure of progression-free survival to overall survival, and it is postulat‐
ed there are possible escape mechanisms in the anti-VEGF pathway and treatment which
results in an aggressive, recurrent tumor [29]. The crossover seen in the AVAglio trial may
have had considerable impact on the true survival data, and in comparison the BELOB [single-
agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in
patients with recurrent glioblastoma] Phase II trial had virtual exclusion of patient cross-over
to the bevacizumab arm, and also surprisingly there were fewer of the above-described adverse
effects of bevacizumab [8]. Additionally, while the predictive value of MGMT promoter
methylation and treatment with temozolomide is well known [32], the prognostic signifi‐
cance in association with anti-angiogenic or other chemotherapeutic agents is less well
understood. Thus, in increasingly more of the recent trials, the MGMT status is included and
required to allow the study of temozolomide-free arms [29]. It has also been noted in prelimi‐
nary clinical trial data that angiopoietin-1/-2 may potentially destabilize vessel and when used
in association with VEGF-A, angiogenic synergy is exhibited and further clinical trials being
undertaken with this hypothesis in mind [27].
Moreover, genetic expression data of glioblastoma subgroups has been recently retrospec‐
tively explored using the AVAglio trial data. To recap, the Cancer Genome Atlas subdivides
the heterogeneous entity of glioblastoma into the following subtypes: proneural, classical, and
mesenchymal (with the previously known neural subtype possibly being an artefact) [33]. In
this most recent study, the addition of bevacizumab is shown to be associated with in‐
creased overall survival in the proneural subtype GBM, with naïve, nonmutated IDH [34]. This
report came as a welcome surprise to the Neuro-Oncology community, as patients with the
proneural subtype lacking IDH mutations have historically a poorer survival compared with
proneural subtype with IDH mutations.
We also note that on preclinical GBM models, it has been shown that bevacizumab induces
hypoxia in treated tumors, which is accompanied by increased glycolytic activity and tumor
invasiveness [35]. This is an area for further research to exploit in view of anaerobic glycolyt‐
ic dependency of glioblastomas and is discussed below in subsection 8 in further detail.
7. Glioma virus therapies
Glioma virus therapies are broadly divided into two categories. Replication-deficient viral
vectors to be used as delivery vehicles for therapeutic, antitumor genes. Second, are the
replication-competent oncolytic viruses that target, infect, and replicate within the host glioma
cell with the intent of destroying the tumor host cells with progeny particle release [36, 37].
The two viruses studied most widely are the adenovirus and herpes simplex (HSV-1) virus.
There are double-stranded DNA viruses, whereby extensive modification may be carried out
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in order for the virus vectors to carry the therapeutic genes under investigation [36]. While
there are multiple Phase I and II clinical trials underway (clinicaltrials.gov), an impetus
remains on the parallel to streamline the efficacy of these viruses to ensure the potency of the
viral vectors without overtly impairing the host immune system response (may want to note
that the mechanism of some of these virus such as the Duke polio virus may be by immune
system induction). Convection enhanced delivery using continuous, positive pressure bulk
flow of the therapeutic virus to the glioma may be undertaken to improve delivery [38, 39].
Specificity may be enhanced for viral entry into the glioma on modification of attachment-
mediating surface proteins and chimeric capsids [25]. Of most interest, are the viral genes being
engineered to be enhanced using hypoxia-responsive promoters in areas of low-hypoxia, a
known glioma phenotype [37, 39].
Of note is the Toca511 trial, with an estimated completion date of November 2017. This is a
multicenter, randomized, Open label Phase II/III study of Toca 511 and Toca FC versus
standard of care. This comprises investigator’s choice of single-agent chemotherapy (lomus‐
tine or temozolomide) or bevacizumab administered to patients with recurrent high-grade
gliomas. Toca 511 (vocimagene amiretrorepvec) is an investigational injectable retroviral
replicating vector (RRV) encoding a yeast-derived prodrug activator enzyme, cytosine
deaminase (CD). Toca 511 selectively infects and spreads through the high-grade glioma cells,
thereby delivering the CD gene and the tumor cells can then produce the CD enzyme.
Toca FC is an orally administered, extended-release version of prodrug 5-fluorocytosine (5-
FC) which is absorbed and carried through the bloodstream. This crosses the blood–brain
barrier and is then converted by the CD enzyme into the active 5-FU, at high concentrations
within the glioma cells infected by Toca 511. 5-FU in turn causes tumor cell apoptosis and
activation of the immune system by the release of tumor-associated antigens and viral proteins
from the dying cells. We look forward to the results of this retroviral replicating vector against
high-grade gliomas and the possible extrapolation to other solid cancers.
8. Tumor treating fields
In 2015, Optune™ became the first FDA-approved therapy for newly diagnosed glioblasto‐
mas in over a decade to demonstrate statistically significant extension of progression free and
overall survival. Optune™ is the brand name for the NovoTTF™ 100A system manufac‐
tured by the commercial stage oncology company Novocure™.
Optune™ is a portable, noninvasive device delivering low-intensity, intermediate frequency,
alternating bidirectional electric fields referred to as Tumor Treating Fields (TTF). The electric
fields are delivered locoregionally via transducer arrays through the shaved scalp. The
mechanism of action is the antimitotic action of the tumor treating fields interfering with cell
division and organelle assembly within the rapidly replicating tumor cells. While micropho‐
tography has shown examples of prolonged mitoses and proliferation arrest, the specificity of
the tumor treating fields for tumor cells only in the absence of an exact mechanism has raised
skepticism within the Neuro-Oncology and Oncology clinician community [40].
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What is undeniable, however, is the two-year survival rate among patients treated with
Optune™ in combination with temozolomide was 48% higher than in patients compared with
patients treated with temozolomide alone [41]. In 2014, the multinational, randomized Phase
III EF-14 trial was halted after successful demonstration of superior progression-free and
overall survivals in patients receiving Optune™ in combination with temozolomide, com‐
pared with temozolomide alone. Patients treated with Optune™, in combination with
temozolomide, demonstrated a statistically significant increase in progression-free survival
compared with temozolomide alone (median progression-free survival of 7.2 months
compared with 4.0 months, hazard ratio = 0.62, p = 0.001. There was also a statistically
significant increase in overall survival compared with temozolomide alone (median overall
survival of 20.5 months compared with 15.6 months, hazard ratio = 0.66, p = 0.004) [40–42]. It
is noted that patients in the control arm received a median of four cycles of temozolamide,
whereas patients in the Optune™ arm received six cycles of temozolamide, which is an
additional confounding factor (patients lived longer therefore they got more temo).
The bottom line here is the availability of Optune™ as a viable option for all patients with
newly diagnosed glioblastoma after successful chemoradiation and stable disease at poten‐
tial initiation of treatment with tumor treating fields [42]. We look forward to the incorpora‐
tion of Optune™ in future trials as a standard arm and with permutations of other
combinatorial therapies.
9. Glycolysis in glioblastomas
Glioblastomas appear to thrive and proliferate in a hypoxic environment, thus relying upon
anaerobic glycolysis [43]. Thus research efforts over the past decade have been toward
maximizing of glycolytic inhibition within the hypoxic glioma environment [44–47].
In their 2015 paper, Sanzey et al. undertook genome-wide transcriptomic analysis of patient-
derived glioblastoma and stem cells to demonstrate a strong upregulation of glycolysis-related
genes in response to severe hypoxia. Glioblastoma xenografts were used to identify seven
glycolytic genes, with knockdown that led to a dramatic murine survival benefit, with
phosphofructokinase-1 [PFK1] and pyruvate dehydrogenase kinase-1 [PDK1] as the most
promising therapeutic targets to address the metabolic escape mechanisms of glioblastomas
[44]. At this point, it is instructive to correlate the high glycolytic states of tumor cells to the
increase in the radioresistance of glioblastomas [48]. A pyruvate dehydrogenase kinase
inhibitor [Dichloroacetate] is used to treat lactic acidosis and is noted to modify tumor
metabolism by activating mitochondrial activity and thus, force glycolytic tumor cells into
oxidative phosphorylation. Dichloroacetate alone demonstrated modest antitumor effects in
both in vitro and in vivo models of glioblastoma and reversed the radiotherapy-induced
glycolytic shift, thereby improving the survival of orthotopic glioblastoma-bearing mice [46].
We look forward to clinical trials modulating the metabolic state of glioblastoma cells and thus,
modify their sensitization to radiotherapy.




The past several decades have seen an explosion of information on the molecular biology of
gliomas and immune environment of cancer. There have been a proliferation of trials involv‐
ing novel signal transduction inhibitors, neoangiogenic, and immune modulatory targets.
Novel methods of delivery of therapeutic molecules and genes have been developed, including
a novel device to deliver nonionizing energy to inhibit mitosis. Imaging criteria have been
developed to better assess response to therapy and aid the clinician and researcher in
evaluating the tumor response to these diverse therapeutic modalities. New genetic testing
has been developed in order to predict prognosis and will soon be incorporated into clinical
trials as Neurooncology moves toward the goal of more personalized cancer therapy.
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